Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control
NCT00621140 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 503
Last updated 2014-02-17
Summary
To investigate efficacy, safety and tolerability of BI 1356 versus placebo
Conditions
- Diabetes Mellitus, Type 2
Interventions
- DRUG
-
linagliptin
active
- DRUG
-
placebo
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Boehringer Ingelheim · Boehringer Ingelheim
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-02-29
- Primary Completion
- 2009-05-31
Countries
- Croatia
- India
- Israel
- Italy
- Malaysia
- Netherlands
- Poland
- Romania
- Slovakia
- Thailand
- Ukraine
Study Locations
More Related Trials
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 135585 XX in Patients With Type 2 Diabetes
NCT01282970 ·Status: COMPLETED ·Phase: PHASE1
-
Japanese P III vs Voglibose and Placebo
NCT00654381 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus
NCT01306214 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of LY2189265 in Japanese Patients With Type 2 Diabetes
NCT01001104 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study
NCT01194830 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Type 2 Diabetes Mellitus
NCT01028963 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability and Preliminary Efficacy of Sublingual Liraglutide in Patients With Type 2 Diabetes Mellitus
NCT05268237 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes
NCT02212925 ·Status: TERMINATED ·Phase: PHASE1
-
A Clinical Study of GRC 8200 in Type 2 Diabetes Mellitus
NCT00836940 ·Status: UNKNOWN ·Phase: PHASE2
-
Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin/Pioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female Subjects
NCT02183636 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus
NCT02589639 ·Status: COMPLETED ·Phase: PHASE4
-
A Phase 2 Study of OPC-262 in Patients With Type 2 Diabetes
NCT00857558 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 Diabetes
NCT03940183 ·Status: COMPLETED ·Phase: PHASE3
-
30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks
NCT01183013 ·Status: COMPLETED ·Phase: PHASE3
-
Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes
NCT00143520 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study of LY3502970 in Japanese Participants With Type 2 Diabetes Mellitus
NCT05086445 ·Status: COMPLETED ·Phase: PHASE1
-
Efficacy and Safety of Empagliflozin (BI 10773) in Type 2 Diabetes Patients on a Background of Pioglitazone Alone or With Metformin
NCT01210001 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety Study of TA-7284 in Patients With Type 2 Diabetes
NCT01413204 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients
NCT01798706 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 187004 in Patients With Type 2 Diabetes Mellitus
NCT01874483 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics and Pharmacodynamics Trial With Linagliptin (BI 1356) 5mg in African American Type 2 Diabetic Patients
NCT00935220 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY3209590 in Japanese Participants With Type 2 Diabetes
NCT03603704 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY3025876 in Participants With Diabetes
NCT01870297 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus
NCT01558271 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus
NCT01029704 ·Status: COMPLETED ·Phase: PHASE2